IPHA Fundamental Analysis - INNATE PHARMA SA-SPONS ADR

Fundamental Rating

IPHA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. IPHA may be in some trouble as it scores bad on both profitability and health. IPHA is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IPHA has reported negative net income.

In the past year IPHA has reported a negative cash flow from operations.

In the past 5 years IPHA always reported negative net income.

IPHA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -49.55%, IPHA is in line with its industry, outperforming 50.75% of the companies in the same industry.

IPHA has a Return On Equity of -895.24%. This is amonst the worse of the industry: IPHA underperforms 81.09% of its industry peers.

		Industry Rank	Sector Rank
ROA	-49.55%
ROE	-895.24%
ROIC	N/A

ROA(3y)-25.61%

ROA(5y)-23.47%

ROE(3y)-227.3%

ROE(5y)-154.41%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IPHA has a better Gross Margin (49.52%) than 75.84% of its industry peers.

In the last couple of years the Gross Margin of IPHA has declined.

The Profit Margin and Operating Margin are not available for IPHA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	49.52%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.

IPHA has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, IPHA has more shares outstanding

IPHA has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -6.26, we must say that IPHA is in the distress zone and has some risk of bankruptcy.

IPHA has a Altman-Z score of -6.26. This is in the lower half of the industry: IPHA underperforms 65.73% of its industry peers.

A Debt/Equity ratio of 11.55 is on the high side and indicates that IPHA has dependencies on debt financing.

With a Debt to Equity ratio value of 11.55, IPHA is not doing good in the industry: 83.52% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	11.55
Debt/FCF	N/A
Altman-Z	-6.26

ROIC/WACCN/A

WACC7.11%

2.3 Liquidity

IPHA has a Current Ratio of 2.21. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 2.21, IPHA is not doing good in the industry: 72.10% of the companies in the same industry are doing better.

A Quick Ratio of 2.21 indicates that IPHA has no problem at all paying its short term obligations.

With a Quick ratio value of 2.21, IPHA is not doing good in the industry: 70.41% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	2.21
Quick Ratio	2.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IPHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.

IPHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -75.86%.

IPHA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.80% yearly.

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.82%

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

3.2 Future

IPHA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.56% yearly.

Based on estimates for the next years, IPHA will show a very strong growth in Revenue. The Revenue will grow by 43.06% on average per year.

EPS Next Y201.85%

EPS Next 2Y66.79%

EPS Next 3Y15.56%

EPS Next 5YN/A

Revenue Next Year-8.95%

Revenue Next 2Y-7.69%

Revenue Next 3Y29.22%

Revenue Next 5Y43.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Based on the Price/Forward Earnings ratio of 6.26, the valuation of IPHA can be described as very cheap.

IPHA's Price/Forward Earnings ratio is rather cheap when compared to the industry. IPHA is cheaper than 99.06% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 23.09, IPHA is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.26

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

IPHA's earnings are expected to grow with 15.56% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y66.79%

EPS Next 3Y15.56%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IPHA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (10/23/2025, 4:30:02 PM)

2.19

+0.1 (+4.78%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-17 2025-09-17/bmo

Earnings (Next)11-13 2025-11-13

Inst Owners10.18%

Inst Owner Change-1.17%

Ins Owners0.92%

Ins Owner ChangeN/A

Market Cap201.85M

Revenue(TTM)6.00M

Net Income(TTM)-46051000

Analysts74.29

Price Target6.12 (179.45%)

Short Float %0.07%

Short Ratio3.12

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-8.34%

PT rev (3m)-7.97%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)21.64%

EPS NY rev (3m)401.03%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-66.54%

Revenue NY rev (3m)-51.3%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.26
P/S	29.03
P/FCF	N/A
P/OCF	N/A
P/B	33.86
P/tB	33.86
EV/EBITDA	N/A

EPS(TTM)-0.6

EYN/A

EPS(NY)0.35

Fwd EY15.96%

FCF(TTM)-0.52

FCFYN/A

OCF(TTM)-0.52

OCFYN/A

SpS0.08

BVpS0.06

TBVpS0.06

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-49.55%
ROE	-895.24%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	49.52%
FCFM	N/A

ROA(3y)-25.61%

ROA(5y)-23.47%

ROE(3y)-227.3%

ROE(5y)-154.41%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

F-Score1

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	11.55
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	10.84%
Cap/Sales	2.82%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.21
Quick Ratio	2.21
Altman-Z	-6.26

F-Score1

WACC7.11%

ROIC/WACCN/A

Cap/Depr(3y)22.77%

Cap/Depr(5y)23.45%

Cap/Sales(3y)3.3%

Cap/Sales(5y)8.22%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.82%

EPS Next Y201.85%

EPS Next 2Y66.79%

EPS Next 3Y15.56%

EPS Next 5YN/A

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

Revenue Next Year-8.95%

Revenue Next 2Y-7.69%

Revenue Next 3Y29.22%

Revenue Next 5Y43.06%

EBIT growth 1Y-31.37%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year283.08%

EBIT Next 3Y30.44%

EBIT Next 5YN/A

FCF growth 1Y-25.63%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-29.1%

OCF growth 3YN/A

OCF growth 5YN/A

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens